JPH0121A - Bone anti-porosis agent - Google Patents
Bone anti-porosis agentInfo
- Publication number
- JPH0121A JPH0121A JP62-110875A JP11087587A JPH0121A JP H0121 A JPH0121 A JP H0121A JP 11087587 A JP11087587 A JP 11087587A JP H0121 A JPH0121 A JP H0121A
- Authority
- JP
- Japan
- Prior art keywords
- bone
- dihydroxyvitamin
- osteotomy
- porosis
- coarsening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims description 20
- 208000010392 Bone Fractures Diseases 0.000 claims description 13
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 claims 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 description 10
- 230000037182 bone density Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010068975 Bone atrophy Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000000236 metacarpal bone Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
本発明は、骨折及び／又は骨切手術後に発生する全身的
な骨の粗層化を防止するための、骨の粗粒化防止剤に関
するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an agent for preventing bone coarsening, which is used to prevent systemic bone coarsening that occurs after bone fracture and/or osteotomy.
近年、特に子供あるいは老人におけるその易骨折性が社
会的問題となっている。その原因として、運動不足１食
物の偏り等、種々指摘されている。In recent years, its tendency to fracture, especially in children and the elderly, has become a social problem. Various causes have been pointed out, including lack of exercise and unbalanced diet.
他方、従来、過去に骨折を経験した者は、そうでない者
に較べて、骨折を起しやすいのではないかという一般的
疑問について、データ的な確認は行われていないし、当
然ながら、易骨折性になることを防ぐ薬理的手段の検討
は、はとんど行われていない。低カルシウム食あるいは
ビタミンＤ欠食で飼育したラットにおいて、実験的骨折
の治癒時に骨の粗義化がおこること、そして粗鬆化した
骨が、最適カルシウム含有食摂取及び１α−とドロキシ
ビタミンＤ３の投与により、回復することが報告されて
いるのみである。On the other hand, there has been no data-based confirmation of the general question of whether people who have experienced a fracture in the past are more likely to suffer a fracture than those who have not, and it goes without saying that Pharmacological means to prevent sexual development have rarely been investigated. In rats fed low-calcium or vitamin D-deficient diets, bone coarsening occurs during healing of experimental fractures, and the coarsened bones are associated with optimal calcium-containing dietary intake and 1α- and droxyvitamin D3 levels. It has only been reported that the disease can be recovered by administration.
本発明者等は該疑問に着目し、その解明を目的として、
骨折侵の治療期間中あるいは骨切手術施行後の治療期間
中に、標準量のカルシウム、リン。The present inventors focused on this question, and with the aim of elucidating it,
Standard doses of calcium and phosphorus during the treatment of fracture lesions or after osteotomy.
ビタミンＤ含有食の摂取下において、全身的な骨の粗層
化が起るかどうか、そしてそれを防止スル薬理的手段に
ついて研究した。ヒトの場合には動物の場合と異なり、
均一な骨折モデルを実験的に作成できないということが
、従来、ヒトの骨折について報告が全くない理由である
。そこで、本発明者等はヒトの骨折のモデルとして変形
性膝関節症骨切手術が該研究に最適であることに着想し
、その治療期間中における全身的な骨の骨密度の変化を
、第２中手骨をその代表部位としてＭＤ法（マイクロデ
ンシトメトリー）で測定した。We investigated whether systemic bone coarsening occurs under the intake of a vitamin D-containing diet, and pharmacological means to prevent it. In humans, unlike animals,
The inability to experimentally create a uniform fracture model is the reason why there have been no reports on human fractures. Therefore, the present inventors came up with the idea that knee osteoarthritis osteotomy surgery would be most suitable for this research as a human fracture model, and investigated the changes in bone density of the whole body during the treatment period. The measurement was performed using the MD method (microdensitometry) using the second metacarpal bone as a representative site.
その結果、その治療期間が２α月間と短期間であるにも
かかわらず、骨密度が症例の年令、骨切手術前の骨密度
の高低に関係なく、すなわち、骨粗髭症患者であるとか
健常人の症例であるとか等の患者要因に無関係に、かな
りの程度に低下していること、及びそれが、骨の骨髄側
゛からの粗層化であることを知見した。すなわち、骨切
手術あるいは骨折を経験した者は、易骨折性が増すこと
が推定された。更に驚（べきことに、骨切手術時乃至治
療期間中、非常に少量の活性型ビタミンＤを継続投与す
ることにより、症例の年令、骨切手術前の骨密度の高低
に関係なく一様に、骨の粗層化を完全に防止することが
できることを知見し、本発明に到達した。As a result, although the treatment period was short (2α months), the bone density remained unchanged regardless of the patient's age or the level of bone density before osteotomy, that is, whether the patient had osteoporosis or not. It was found that there was a considerable decrease regardless of patient factors such as whether the case was a healthy person, and that this was due to coarsening of the bone from the bone marrow side. In other words, it was estimated that those who had undergone osteotomy or fracture had an increased tendency to fracture. Furthermore, surprisingly, by continuously administering a very small amount of active vitamin D during osteotomy surgery and the treatment period, the effect is uniform regardless of the age of the patient or the level of bone density before osteotomy surgery. The inventors have now discovered that bone coarsening can be completely prevented, and have arrived at the present invention.
すなわち、本発明は、活性型ビタミンＤを有効成分とす
る、骨折及び／又は骨切手術後に発生する全身的な骨の
粗層化を防止するための骨の粗鬆化防止剤である。That is, the present invention is a bone coarsening inhibitor that contains active vitamin D as an active ingredient and is used to prevent systemic bone coarsening that occurs after bone fracture and/or osteotomy.
本発明における活性型ビタミンＤとしては、例えば、１
α−ヒドロキシビタミンＤ１１α 、２４−ジヒドロキ
シビタミンＤ、 １α 、２５−ジヒドロキシビタミ
ンＤ、１α、 ２４．２５−トリヒドロキシビタミン
Ｄ１２４，２４− Ｆ ２ １α 、２５−ジヒドロ
キシビタミンＤ及び２６，２６，２６，２７，２７，２
７．− Ｆ ｓ −１α 、２５−ジヒドロキシビタミ
ンＤが挙げられる。The active vitamin D in the present invention includes, for example, 1
α-hydroxyvitamin D11α, 24-dihydroxyvitamin D, 1α, 25-dihydroxyvitamin D, 1α, 24.25-trihydroxyvitamin D124,24-F21α, 25-dihydroxyvitamin D and 26,26,26,27 ,27,2
7. -Fs-1α, 25-dihydroxyvitamin D.
好ましいのは、それぞれの活性型ビタミンＤ３である。Preferred is the respective active form of vitamin D3.
これらの有効成分は公知の方法で、適当な賦型剤等を用
いて軟カプセル剤、硬カプセル剤。These active ingredients can be formulated into soft capsules or hard capsules using appropriate excipients using known methods.
錠剤、シロップ等の経口剤あるいは注射剤にして使用で
きる。有効成分の投与量は、通常０．０１〜１０μｇ／
日／人程度であり、投与回数は、通常〜３回／日であり
、このような条件を満足する。It can be used in the form of oral preparations such as tablets and syrup, or injections. The dosage of the active ingredient is usually 0.01 to 10 μg/
The number of administrations is usually 3 times/day, which satisfies these conditions.
うに製剤を調製するのが好ましい。Preferably, a sea urchin formulation is prepared.
本発明において、活性型ビタミンＤを有効成：とする製
剤は、骨折及び／又は骨切手術の前後）ら、骨折及び／
又は骨切が治癒するまでの期間１与される。通常は約２
〜３ケ月の期間である。In the present invention, preparations containing active vitamin D as an active ingredient can be used to treat bone fractures and/or osteotomy (before and after bone fractures and/or osteotomy).
Or one period is given for the osteotomy to heal. Usually about 2
The period is ~3 months.
本発明の製剤は、カルシウム（化合物）、す；（化合物
）、カルチトニン鎮痛剤、蛋白同化ホノモン等と併用可
能であることはもちろんである。It goes without saying that the preparation of the present invention can be used in combination with calcium (compound), sulphate (compound), calcitonin analgesic, protein anabolic monomones, and the like.
以下、実施例により本発明を詳述する。Hereinafter, the present invention will be explained in detail with reference to Examples.
実施例１
変形性膝関節症患者（年令５２乃至７６オ、平均６６．
６オ）９例について、患者の同意を得た上で、骨切手術
に先立つ１週間前から、１α−ヒドロニジビタミンＤ３
（１α−（ＯＨ）０３ ）１μ９゜日の投与を開始し
、手術後２ケ月間投与を継続また。該期間中、食事は標
準量のカルシウム、す：ビタミンＤの含有食とした。骨
切手術前（投与［１始前）及び骨切手術２ケ月後の骨の
評価は、ＭＤ上 法（井よ、串田、宮本、矢島、伊丹
、山下、骨代謝、１３巻、１８７〜１９５ （１９８０
） ）により行った。Example 1 Patients with knee osteoarthritis (age 52-76, average age 66.
6e) In 9 cases, with the patient's consent, 1α-hydronidivitamin D3 was administered for one week prior to osteotomy surgery.
Administration of (1α-(OH)03) 1μ was started for 9 days and continued for 2 months after the surgery. During this period, the diet consisted of a diet containing standard amounts of calcium and vitamin D. Bone evaluation before osteotomy surgery (before administration) and 2 months after osteotomy surgery was performed using the MD method (Iyo, Kushida, Miyamoto, Yajima, Itami, Yamashita, Bone Metabolism, Vol. 13, 187-195. (1980
)).
汗 骨切手術前及び骨切手術２ケ月後の、ＭＤ法の各
りゝ 指標の平均値は、第１表に示す通りであり、ど
の交 指標の悪化も認められなかった。Sweat The average values of each index of the MD method before the osteotomy surgery and 2 months after the osteotomy surgery are shown in Table 1, and no deterioration of any of the intersection indexes was observed.
ン 第１表
１し
骨
ヤ 症例ごとの検討でも、１α−（ＯＨ）Ｄａの効
′ 果はＧ５１ｉｎ 、 ＧＳｍａｘ テ有意であル
コトカχ２じ 検定で示された。すなわち比較例１と
の比較検定ン・ において、ＧＳｎ＋ｉｎ ： ｚ２
−８．９６ （Ｐ＜ ０．０１ ）Ｉｌｌ ＧＳｍ
ａｘ：ｚ２−６．３２（Ｐ＜０．０５）ｒあり、本発明
の骨の粗鬆化防止の効果が立証された。Table 1 1. In the case-by-case study, the effect of 1α-(OH)Da on G51in and GSmax was shown to be significant using the Rukotka chi-square test. That is, in the comparison test with Comparative Example 1, GSn+in: z2
-8.96 (P<0.01)Ill GSm
ax: z2-6.32 (P<0.05) r, proving the effect of the present invention in preventing bone coarsening.
比較例１
変形性膝関節症患者（年令６１乃至７３才、平均６９．
７オ）７例について、実施例１と同様の測定を行った。Comparative Example 1 Patients with osteoarthritis of the knee (age 61 to 73, average age 69.
7e) The same measurements as in Example 1 were performed for 7 cases.
但しこの場合には１α−（ＯＨ）Ｄ３の投与は行わなか
った。食事については実施例１の場合と同様である。そ
の結果は第２表に示す通りであり、ＭＣ１，ｄについて
は悪化は認められなかったが、骨密度関係の指標、特に
３３ ｗｉｎの悪化か認められ骨の粗粒化が起ったこと
が示された。However, in this case, 1α-(OH)D3 was not administered. The meals were the same as in Example 1. The results are shown in Table 2, and although no deterioration was observed in MC1,d, deterioration in bone density-related indicators, especially 33win, was observed, indicating that bone coarsening had occurred. Shown.
第２表
なおＭＤ法とは、Ｘ線像の黒化度の基準として、アルミ
階段（Ｇ ｒａＹ Ｓ ｃａｆｅ）とともに平部のＸ
線像を藏影し、第■中手骨の近位端と遠位端の中間点で
、デンシトメータを用いて、その黒化度を測定し、コン
ピュータを用いて、ピーク高さをアルミ階段の段数に換
算し、骨幅（Ｄ）、骨髄幅（ｄ）、骨皮質幅指数［ＭＤ
Ｉ （−（Ｄ二ｄ）／Ｄ）コ、骨皮質の密度の指標（
ＧＳｍａｘ ） 、 （骨皮質＋骨髄）の密度の指標
（ＧＳｌｌｉｎ ＞ 、単位長さ当りの骨密度の指標（
ΣＧＳ／Ｄ）等を求め、これらの指標から、骨萎縮（骨
の粗粒化）を判定する方法である。Table 2 Note that the MD method is used as a standard for the degree of blackening of X-ray images.
The line image was shaded, the degree of darkening was measured using a densitometer at the midpoint between the proximal and distal ends of the first metacarpal, and the peak height was calculated using a computer. Converted to the number of steps, bone width (D), bone marrow width (d), bone cortical width index [MD
I (-(D2d)/D), index of bone cortex density (
GSmax), index of density of (bone cortex + bone marrow) (GSllin >, index of bone density per unit length (
This is a method of determining bone atrophy (coarsening of bones) from these indices.
Claims (1)
は骨切手術後に発生する全身的な骨の粗鬆化を防止する
ための骨の粗鬆化防止剤。 ２、活性型ビタミンＤが、１α−ヒドロキシビタミンＤ
、１α，２４−ジヒドロキシビタミンＤ、１α，２５−
ジヒドロキシビタミンＤ、２４，２５−ジヒドロキシビ
タミンＤ、１α，２４，２５−トリヒドロキシビタミン
Ｄ、２４，２５−Ｆ＿２−１α，２５−ジヒドロキシビ
タミンＤ及び２６，２６，２６，２７，２７，２７−Ｆ
＿６−１α，２５−ジヒドロキシビタミンＤからなる群
から選ばれたものである、特許請求の範囲第１項記載の
骨の粗鬆化防止剤。[Scope of Claims] 1. A bone porosis inhibitor containing active vitamin D as an active ingredient for preventing systemic bone porosis that occurs after bone fracture and/or osteotomy surgery. 2. Active vitamin D is 1α-hydroxyvitamin D
, 1α,24-dihydroxyvitamin D, 1α,25-
Dihydroxyvitamin D, 24,25-dihydroxyvitamin D, 1α,24,25-trihydroxyvitamin D, 24,25-F_2-1α,25-dihydroxyvitamin D and 26,26,26,27,27,27-F
_6-1α,25-dihydroxyvitamin D The anti-bone osteoporosis agent according to claim 1, which is selected from the group consisting of _6-1α,25-dihydroxyvitamin D.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11087587A JPS6421A (en) | 1987-02-27 | 1987-05-08 | Preventive for osteoporosis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62-43036 | 1987-02-27 | ||
| JP4303687 | 1987-02-27 | ||
| JP11087587A JPS6421A (en) | 1987-02-27 | 1987-05-08 | Preventive for osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0121A true JPH0121A (en) | 1989-01-05 |
| JPS6421A JPS6421A (en) | 1989-01-05 |
Family
ID=26382781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11087587A Pending JPS6421A (en) | 1987-02-27 | 1987-05-08 | Preventive for osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6421A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0399022A (en) * | 1989-09-12 | 1991-04-24 | Teijin Ltd | Medicine of bone cacochymia and evaluation of bone metabolism state |
| DE4212122C2 (en) * | 1992-04-10 | 1999-07-29 | Hesch Rolf Dieter Prof Dr Med | Dietary low-energy food to support medical and non-medical measures against osteoporosis |
| US7044546B2 (en) | 2002-08-14 | 2006-05-16 | Johnson Safety, Inc. | Headrest-mounted monitor |
| US10556549B2 (en) | 2015-07-08 | 2020-02-11 | Voxx International Corporation | Headrest-integrated entertainment system |
| US10397684B2 (en) | 2016-01-05 | 2019-08-27 | Voxx International Corporation | Wireless speaker system |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59186956A (en) * | 1983-04-07 | 1984-10-23 | Teijin Ltd | 24-hydroxy-25-dehydrovitamin d3, its production and calcium regulating agent containing the same as active constituent |
| JPS59190962A (en) * | 1983-04-11 | 1984-10-29 | Teijin Ltd | 24-oxo-25-dehydrovitamin d3, its production and calcium regulating agent containing the same as active constituent |
| JPS6048963A (en) * | 1983-08-24 | 1985-03-16 | Teijin Ltd | 26-halogenated vitamin d3 derivative, its preparation and drug comprising it as active ingredient |
| AU589113B2 (en) * | 1984-01-30 | 1989-10-05 | Wisconsin Alumni Research Foundation | Side-chain unsaturated 1-hydroxyvitamin d compounds |
| JPS60185715A (en) * | 1984-03-05 | 1985-09-21 | Teijin Ltd | Bone formation accelerator |
| JPS61189219A (en) * | 1985-02-15 | 1986-08-22 | Fujimoto Seiyaku Kk | Preparation containing stable activated vitamin d3 |
-
1987
- 1987-05-08 JP JP11087587A patent/JPS6421A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69629184T2 (en) | USE OF VITAMIN D2 OR VITAMIN D4 DERIVATIVES FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING SECONDARY HYPERPARATHYROIDISM | |
| BERNSTEIN et al. | Use of sodium fluoride in the treatment of osteoporosis | |
| JPH0772138B2 (en) | Pharmaceutical complex for increasing bone mass | |
| Silver et al. | Osteoporosis and Aging: Current Update. | |
| Steiner et al. | Importance of dietary cholesterol in man | |
| JPH10504839A (en) | How to reduce the risk of non-vertebral fracture | |
| Hunt et al. | Bone disease induced by anticonvulsant therapy and treatment with calcitriol (1, 25-dihydroxyvitamin D3) | |
| Wasserman et al. | Osteoporosis: the state of the art in 1987: a review | |
| Branco et al. | Notes on a rare case of essential osteolysis | |
| Breslau | Calcium, estrogen, and progestin in the treatment of osteoporosis | |
| Marder et al. | Calcitriol deficiency in idiopathic juvenile osteoporosis | |
| JPH0121A (en) | Bone anti-porosis agent | |
| Lane | The Osteoporosis Book: A Guide for patients and their families | |
| Horwith et al. | Hereditary bone dysplasia with hyperphosphatasaemia: response to synthetic human calcitonin | |
| EP0381750B1 (en) | Method for treating and preventing loss of bone mass | |
| EP0337938A2 (en) | 19-Norprogesterone derivatives in the treatment of osteoporosis | |
| Touliatos et al. | Hypoparathyroidism counteracts risk factors for osteoporosis | |
| Kesson et al. | Generalized osteoporosis in old age | |
| Gollop et al. | Prenatal diagnosis of thalidomide syndrome | |
| JP4652689B2 (en) | Use of calmodulin to promote bone regeneration | |
| JPH02231425A (en) | Method and composition for medical treatment of human osteoporosis | |
| CN108125941A (en) | A kind of application of E-10- hydroxyls -2- decylenic acids in the drug or health products for preparing anti-curing osteoporosis | |
| Franklyn | Progeria in siblings | |
| McClendon et al. | The curative effect of a high-calcium diet on senile osteoporosis | |
| JP2001503728A (en) | Estrogens and parathyroid hormone for the treatment of osteoporosis |